Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) EBIT Margin (2016 - 2025)

Lineage Cell Therapeutics' EBIT Margin history spans 16 years, with the latest figure at 99.09% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 7908.0% year-over-year to 99.09%; the TTM value through Dec 2025 reached 251.57%, down 2547.0%, while the annual FY2025 figure was 251.57%, 2547.0% down from the prior year.
  • EBIT Margin reached 99.09% in Q4 2025 per LCTX's latest filing, up from 102.85% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 56.48% in Q4 2021 to a low of 1803.07% in Q1 2021.
  • Average EBIT Margin over 5 years is 403.3%, with a median of 289.91% recorded in 2021.
  • Peak YoY movement for EBIT Margin: surged 168094bps in 2022, then tumbled -36297bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 56.48% in 2021, then tumbled by -514bps to 346.68% in 2022, then rose by 12bps to 304.69% in 2023, then skyrocketed by 42bps to 178.17% in 2024, then surged by 44bps to 99.09% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's EBIT Margin are 99.09% (Q4 2025), 102.85% (Q3 2025), and 715.37% (Q2 2025).